ヒストンデアセチラーゼ1治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Histone Deacetylase 1 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0411
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:160
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Histone Deacetylase 1 – Pipeline Review, H2 2019
Summary

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 33 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 1 – Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 5, 14 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Genetic Disorders, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Mycosis Fungoides, Non-Small Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Pancreatic Cancer, Parkinson’s Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Thalassemia, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer’s Disease, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Bone Disorders, Central Nervous System (CNS) Tumor, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gliosarcoma, Hematological Tumor, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Cancer, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Solid Tumor and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Overview
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Companies Involved in Therapeutics Development
4D Pharma Plc
4SC AG
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Curis Inc
IRBM Science Park SpA
Italfarmaco SpA
Jubilant Biosys Ltd
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
Regenacy Pharmaceuticals LLC
Shuttle Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Drug Profiles
ACY-1035 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1071 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Dormant Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Discontinued Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by 4D Pharma Plc, H2 2019
Pipeline by 4SC AG, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Curis Inc, H2 2019
Pipeline by IRBM Science Park SpA, H2 2019
Pipeline by Italfarmaco SpA, H2 2019
Pipeline by Jubilant Biosys Ltd, H2 2019
Pipeline by Medivir AB, H2 2019
Pipeline by MEI Pharma Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
Pipeline by Regenacy Pharmaceuticals LLC, H2 2019
Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
Pipeline by Syndax Pharmaceuticals Inc, H2 2019
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019

【掲載企業】

4D Pharma Plc
4SC AG
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Curis Inc
IRBM Science Park SpA
Italfarmaco SpA
Jubilant Biosys Ltd
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
Regenacy Pharmaceuticals LLC
Shuttle Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヒストンデアセチラーゼ1治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆